{"id":295332,"date":"2022-05-27T00:00:00","date_gmt":"2022-05-27T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneop0003-2022-biopharma-diabetic-macular-edema-diabetic-retinopathy-unmet-need-unmet-need\/"},"modified":"2026-05-05T11:18:36","modified_gmt":"2026-05-05T11:18:36","slug":"unneop0003-2022-biopharma-diabetic-macular-edema-diabetic-retinopathy-unmet-need-unmet-need-diabetic-macular-edema-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneop0003-2022-biopharma-diabetic-macular-edema-diabetic-retinopathy-unmet-need-unmet-need-diabetic-macular-edema-us\/","title":{"rendered":"Diabetic Macular Edema \/ Diabetic Retinopathy &#8211; Unmet Need &#8211; Unmet Need &#8211; Diabetic Macular Edema (US\/EU)"},"content":{"rendered":"<p>Diabetic macular edema (<abbr data-abbreviation-entity=\"4790\" title=\"diabetic macular edema\">DME<\/abbr>) is caused by diabetes and is characterized by leaking fluid from abnormal blood vessels in the eye; this fluid can lead to swelling of the macula and visual impairment. Intravitreal vascular endothelial growth factor (<abbr data-abbreviation-entity=\"4987\" title=\"vascular endothelial growth factor\">VEGF<\/abbr>) inhibitors, such as Regeneron \/ Bayer\u2019s Eylea, Roche \/ Novartis\u2019s Lucentis, and Roche\u2019s Avastin, are the most common pharmacotherapies for treating <abbr data-abbreviation-entity=\"4790\" title=\"diabetic macular edema\">DME<\/abbr>, owing to their proven efficacy and safety. AbbVie\u2019s Ozurdex and Alimera Sciences\u2019 Iluvien, two long-acting corticosteroid implants, are also used to treat <abbr data-abbreviation-entity=\"4790\" title=\"diabetic macular edema\">DME<\/abbr>. However, these drugs all have clinical shortcomings in terms of efficacy, safety, and\/or delivery, creating opportunities for new and improved alternatives. Our content examines the key treatment drivers and analyzes the greatest areas of unmet need, thereby presenting the opportunities in this space.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the treatment drivers and goals for <abbr data-abbreviation-entity=\"4790\" title=\"diabetic macular edema\">DME<\/abbr>?<\/li>\n<li>What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?<\/li>\n<li>How do current therapies perform on key treatment drivers and goals for <abbr data-abbreviation-entity=\"4790\" title=\"diabetic macular edema\">DME<\/abbr>?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in <abbr data-abbreviation-entity=\"4790\" title=\"diabetic macular edema\">DME<\/abbr>?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to U.S. and European ophthalmologists for a hypothetical new <abbr data-abbreviation-entity=\"4790\" title=\"diabetic macular edema\">DME<\/abbr> drug?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>Unmet Need<\/em> provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.<\/p>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 30 European ophthalmologists fielded in March 2022<\/p>\n<p><strong>Key companies:<\/strong> Roche, Regeneron, Novartis, Bayer, AbbVie, Alimera Sciences<\/p>\n<p><strong>Key drugs:<\/strong> Eylea, Lucentis, Avastin, Ozurdex, Iluvien<\/p>\n","protected":false},"template":"","class_list":["post-295332","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-diabetic-macular-edema","biopharma-therapy-areas-diabetic-retinopathy","biopharma-therapy-areas-ophthalmology","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295332","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295332\/revisions"}],"predecessor-version":[{"id":295483,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295332\/revisions\/295483"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295332"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}